A multicenter, open-label study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CNTY-101 in patients with relapsed or refractory CD19-positive B-cell lymphomas.
Now Recruiting
Learn more about Century’s current Phase 1 clinical trial, ELiPSE-1, with study ID number: NCT05336409 at clinicaltrials.gov.